Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 516,926
  • Shares Outstanding, K 34,763
  • Annual Sales, $ 42,300 K
  • Annual Income, $ -53,340 K
  • 60-Month Beta 1.03
  • Price/Sales 12.21
  • Price/Cash Flow N/A
  • Price/Book 17.83
Trade AVEO with:

Options Overview Details

View History
  • Implied Volatility 11.21% ( +1.40%)
  • Historical Volatility 101.55%
  • IV Percentile 6%
  • IV Rank 4.27%
  • IV High 188.85% on 02/03/22
  • IV Low 3.28% on 10/27/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 131
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 14,019

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate -0.09
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +80.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.71 +1.09%
on 11/03/22
14.89 -0.13%
on 11/15/22
+0.10 (+0.64%)
since 10/25/22
3-Month
7.33 +102.86%
on 08/29/22
14.95 -0.54%
on 10/18/22
+6.70 (+82.01%)
since 08/25/22
52-Week
3.06 +385.95%
on 01/28/22
14.95 -0.54%
on 10/18/22
+8.34 (+127.72%)
since 11/24/21

Most Recent Stories

More News
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

AVEO : 14.87 (+0.07%)
QURE : 26.90 (+2.05%)
ETON : 2.99 (unch)
IMCR : 61.54 (-2.73%)
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEO : 14.87 (+0.07%)
ETON : 2.99 (unch)
IMCR : 61.54 (-2.73%)
PALI : 3.75 (-5.54%)
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

AVEO : 14.87 (+0.07%)
BLUE : 7.59 (+0.93%)
ETON : 2.99 (unch)
IMCR : 61.54 (-2.73%)
AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AVEO : 14.87 (+0.07%)
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe

Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several...

AVEO : 14.87 (+0.07%)
ITCI : 52.23 (+2.03%)
ETON : 2.99 (unch)
IMCR : 61.54 (-2.73%)
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

AVEO : 14.87 (+0.07%)
ETON : 2.99 (unch)
MNPR : 2.58 (+1.18%)
IMCR : 61.54 (-2.73%)
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study

Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.

AVEO : 14.87 (+0.07%)
ETON : 2.99 (unch)
INBX : 30.33 (+3.02%)
IMCR : 61.54 (-2.73%)
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

AVEO : 14.87 (+0.07%)
ETON : 2.99 (unch)
ARQT : 17.97 (+1.35%)
IMCR : 61.54 (-2.73%)
What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

AVEO : 14.87 (+0.07%)
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

NBIX : 122.15 (+2.67%)
MDY : 467.50 (+0.52%)
CPRX : 16.97 (-0.35%)
AVEO : 14.87 (+0.07%)
IMCR : 61.54 (-2.73%)
AMGN : 283.74 (+0.12%)
VRTX : 312.98 (-1.01%)
REGN : 736.23 (+0.12%)
GILD : 86.26 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

3rd Resistance Point 14.91
2nd Resistance Point 14.89
1st Resistance Point 14.88
Last Price 14.87
1st Support Level 14.85
2nd Support Level 14.83
3rd Support Level 14.82

See More

52-Week High 14.95
Last Price 14.87
Fibonacci 61.8% 10.41
Fibonacci 50% 9.01
Fibonacci 38.2% 7.60
52-Week Low 3.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar